A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (RENACOL)

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (Macrophage Antibody To Inhibit Immune Suppression in RENAl Cell and COLon Carcinomas)

Bexmarilimab treatment has demonstrated tolerable safety profile and anticancer efficacy in some subjects with advanced malignancies. This is the first study to investigate the effect of single neoadjuvant dose of anti-CLEVER-1 antibody bexmarilimab prior to radical surgery of renal cell and colon cancers. We expect that the single dose will demonstrate measurable effects on the tumour immunological microenvironment as well as systemic effects on subject´s immunological status and that this evidence may be used to guide future neoadjuvant studies. There will be a dose escalation to investigate the effect of different doses of bexmarilimab. In addition to subjects receiving single neoadjuvant dose of bexmarilimab, there will be an observational cohort without Investigational Medicinal Product (IMP) for either cancer. All patients participating in the study (whether in investigational or observational cohort) will attend each visit and are assessed for the same endpoints.

Study Overview

• Status: Withdrawn
• Conditions: Carcinoma, Renal Cell; Carcinoma Colon
• Intervention / Treatment: Drug: bexmarilimab

• Study Type: Interventional
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Finland
  • Turku, Finland, 20521
    • Turku University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Provision of signed and dated informed consent form.
2. Ability and stated willingness to comply with all study procedures and availability for the duration of the study.
3. Male or female, aged > 18 years.
4. Adequate general health (ECOG 0 or 1) to undergo planned radical surgery for renal cell or colon cancer.
5. Adequate bone marrow, liver and kidney function defined as: Blood white blood cell ≥ lower limit of normal Blood neutrophil count ≥ 1x109/L Blood platelet count ≥ 100x109/L Blood haemoglobin ≥ 9.0 g/dL Creatinine clearance > 40 mL/min calculated by Cockcroft-Gault formula Aspartate Aminotransferase (AST) ≤ 3 X Upper Limit of Normal (ULN) Alanine Aminotransferase (ALT) ≤ 3 X ULN Bilirubin ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL

6. Histologically confirmed clear cell renal cell cancer planned to be treated with surgery with curative intent (Renal cell cancer cohort). In renal cell observation cohort, histological confirmation not mandatory.

   or Histologically confirmed adenocarcinoma of the colon planned to be treated with surgery with curative intent (Colon cancer cohort).

   Additional inclusion criteria for subjects planned to have a single neoadjuvant dose of CLEVER-1 antibody bexmarilimab:

7. For females of reproductive potential: use of highly effective contraception* for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of single neoadjuvant dose of bexmarilimab administration.

8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 12 weeks after the administration of single neoadjuvant dose of bexmarilimab.

   • Women of childbearing potential i.e. not post-menopausal or surgically sterilised must use highly effective methods of contraception. For example, combined estrogen and progestogen hormonal contraception to inhibit ovulation; progestogen-only hormonal contraception to inhibit ovulation; intra-uterine device (IUD); intrauterine hormone-releasing system (IUS) or vasectomised partner to prevent pregnancy or abstain. Abstinence must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence such as calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception during heterosexual activity for the duration of the trial and for at least 12 weeks following the study drug administration. In addition, barrier contraception (with or without spermicide) may be used but this should not be considered as an adequate form of contraception on its own.

Fertile men whose partners could be of childbearing potential should routinely use a condom for 12 weeks after the study drug administration. The partner, if not pregnant, should also use a reliable form of contraception such as the oral contraceptive pill or an IUD.

Exclusion Criteria:

1. Evidence of metastatic disease making subject not eligible for surgical resection, except for local nodal metastatic disease.
2. History of previous treatment for renal cell cancer (renal cell cancer cohorts) or colon cancer (colon cancer cohorts).
3. Less than 3 months since the last dose of any cancer therapy prior to consenting.
4. Less than 4 weeks since any major surgery.
5. Treatment with any investigational agent within 4 weeks before consenting.
6. History of another malignancy without curative treatment or suspicion of disease recurrence.
7. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure New York Heart Association (NYHA) class 2, Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial.
8. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment.
9. Confirmed human immunodeficiency virus infection.
10. Confirmed hepatitis B or C virus infection.
11. Symptomatic cytomegalovirus infection.
12. Subjects with active autoimmune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).
13. The subject requires systemic corticosteroid or other immunosuppressive treatment.
14. Subjects with organ transplants.
15. Subjects in dialysis.
16. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit.
17. Subject is unwilling or unable to comply with treatment and trial instructions.
18. Pregnancy or lactation.
19. Medical history of chronic ulcers, abnormal liver function or previous liver problems/diseases

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Renal cell intervention 1.0 mg/kg	Drug: bexmarilimab; A single neoadjuvant dose will be administered prior to surgery.
Experimental: Renal cell intervention 3.0 mg/kg	Drug: bexmarilimab; A single neoadjuvant dose will be administered prior to surgery.
Experimental: Renal cell intervention 10 mg/kg	Drug: bexmarilimab; A single neoadjuvant dose will be administered prior to surgery.
No Intervention: Renal cell Observation
Experimental: Colon cancer intervention 1.0 mg/kg	Drug: bexmarilimab; A single neoadjuvant dose will be administered prior to surgery.
Experimental: Colon cancer intervention 3.0 mg/kg	Drug: bexmarilimab; A single neoadjuvant dose will be administered prior to surgery.
Experimental: Colon cancer intervention 10 mg/kg	Drug: bexmarilimab; A single neoadjuvant dose will be administered prior to surgery.
No Intervention: Colon cancer Observation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events ≥Grade 3 during the 28 days (4 weeks) following the single dose of bexmarilimab and surgical adverse events ≥Grade 3 during the 14days (2 weeks) following the surgery	Adverse Events ≥Grade 3 according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 during the 28 days (4 weeks) following the single dose of bexmarilimab and surgical adverse events ≥Grade 3 according to the Clavien-Dindo classification occurring during the 14 days (2 weeks) following the surgery	28 days and 14 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Adverse events until the follow-up visit on Day 84	Day 84
Radiological response rate according to the response evaluation criteria in solid tumours (RECIST 1.1) (Day 13)	Day 13
Pathological response rate evaluated with Ryan tumour regression grade (Day 14), percentage of tumour cell necrosis	Day 14
Long-term clinical benefit measured by disease-free survival assessed at 1, 3 and 5 years	1, 3, and 5 years

Collaborators and Investigators

• Sponsor: Faron Pharmaceuticals Ltd
• Investigators: Principal Investigator: Peter Boström, Turku University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 7, 2021
• Primary Completion (Actual): January 28, 2022
• Study Completion (Actual): January 28, 2022

Study Registration Dates

• First Submitted: October 22, 2021
• First Submitted That Met QC Criteria: October 22, 2021
• First Posted (Actual): November 3, 2021

Study Record Updates

• Last Update Posted (Actual): May 11, 2022
• Last Update Submitted That Met QC Criteria: May 5, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Carcinoma, Renal Cell; Carcinoma
• Other Study ID Numbers: FP2CLI003; 2021-001030-19 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No